Telavancin Observational Use Registry (TOUR) (TOUR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02288234

Recruitment Status : Completed

First Posted : November 11, 2014

Last Update Posted : January 15, 2019

Sponsor:

Information provided by (Responsible Party):

Cumberland Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	June 2017
Actual Study Completion Date :	October 2017

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Reilly J, Jacobs MA, Friedman B, Cleveland KO, Lombardi DA, Castaneda-Ruiz B. Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™). Drugs Real World Outcomes. 2020 Sep;7(3):179-189. doi: 10.1007/s40801-020-00191-x.

To Top